Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer
(DTC). The traditional first line treatment for patients with advanced DTC after surgical
resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with
lung metastases will achieve a complete response to RAI therapy, and this therapy carries the
risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.